THIS WEBSITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY.

I certify that I am a healthcare professional in the US.

NO

For the treatment of moderate to severe Vasomotor Symptoms (VMS)—commonly referred to as hot flashes and night sweats—due to menopause1,2

Woman and doctor holding VEOZAHTM (fezolinetant) logo fire extinguisher

PUT VEOZAH in YOUR PATIENTS’ HANDS TODAY

Help your patients access VEOZAH

VEOZAH Support SolutionsSM offers support to help patients who have been prescribed VEOZAH address potential access and affordability challenges, whether they have commercial prescription insurance, have government insurance (eg, Medicare, Medicaid), or are uninsured.

VEOZAHTM (fezolinetant) Savings Card
VEOZAHTM (fezolinetant) Savings Card

For eligible patients with commercial prescription insurance

Patients may pay $0 for the first monthly prescription and may pay as little as $30 per monthly refill*
  • A patient must have a valid prescription for VEOZAH, meet the eligibility requirements, and present the VEOZAH Savings Card to their preferred pharmacy
  • The program has an annual maximum copay assistance limit of $1,300 per calendar year
  • There are no income requirements
  • The program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program

If patients are not eligible for the Savings Card, they can contact VEOZAH Support Solutions to find out what other savings options may be available. Patients can call 1-866-239-1637 or go to VEOZAHSupportSolutions.com to sign up.

Terms & Conditions

By enrolling in the VEOZAH Savings Program (“Program”), the patient acknowledges that they currently meet the eligibility criteria and will comply with the following terms and conditions: The Program is for eligible patients with commercial prescription insurance and is good for use only with a valid prescription for VEOZAHTM (fezolinetant) at the time the prescription is dispensed by the pharmacy. The Program has an annual maximum copay assistance limit of $1,300 per calendar year. After the annual maximum on copay assistance is reached, patient will be responsible for the remaining monthly out-of-pocket costs for VEOZAH. The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patients who move from commercial insurance to federal or state prescription health insurance will no longer be eligible, and agree to notify the Program of any such change. Patients agree not to seek reimbursement from any health insurance or third party for all or any part of the benefit received by the patient through the Program. This offer is not conditioned on any past, present, or future purchase of VEOZAH. This offer is not transferrable, has no cash value, and cannot be combined with any other offer, free trial, prescription savings card, or discount (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator” or “maximizer” programs). The full value of the Program benefits is intended to pass entirely to the eligible patient. No other individual or entity (including, without limitation, third party payers, pharmacy benefit managers, or the agents of either) is entitled to receive any benefit, discount or other amount in connection with this Program. This offer is not health insurance and is only valid for patients in the 50 United States, Washington DC, and Puerto Rico. This offer is not valid for cash paying patients. This Program is void where prohibited by law. No membership fees. It is illegal to sell, purchase, trade, counterfeit, duplicate, or reproduce, or offer to sell, purchase, trade, counterfeit, duplicate or reproduce the card. This offer will be accepted only at participating pharmacies. Certain rules and restrictions apply. Astellas reserves the right to revoke, rescind, or amend this offer without notice for any reason (including to ensure that the offer is utilized solely for the patient’s benefit).

Eligibility requirements and terms and conditions apply.

Woman and doctor looking at iPad

For patients with no prescription insurance

The Astellas Patient Assistance Program (PAP)provides VEOZAH at no cost to uninsured patients who meet the program eligibility requirements.

To find out if your patient is eligible, you or your patient can call VEOZAH Support Solutions at 1-866-239-1637, Monday through Friday, 8:00 AM to 8:00 PM ET. Information may also be provided about other assistance options that may be available.


For patients with Medicare Part D, Medicaid, or other government insurance

Information may be provided about other assistance options that may be available, such as Medicare Extra Help.


VEOZAH Support Solutions can also help with benefits verification and provide information regarding prior authorization processes and potential eligibility for various VEOZAH Support Solutions programs.


Subject to eligibility restrictions. Program terms and conditions apply. Void where prohibited by law.

VEOZAH Support Solutions has no control over the decisions of, and does not guarantee support from, independent third parties.

Woman holding VEOZAHTM (fezolinetant) logo fire extinguisher

How to Submit a Prescription for VEOZAH

  1. Submit the prescription directly to the patient’s preferred pharmacy. Your patient can then fill the prescription at their preferred pharmacy and begin treatment.
  2. If your patient experiences an insurance-related delay, you can submit the prescription electronically to Sonexus Health Pharmacy Services. VEOZAH Support Solutions can help patients on VEOZAH address potential access and affordability challenges. 

    Submit the prescription from your electronic medical record system and select the following: Sonexus Health Pharmacy Services, NPI Number: 1447680210

 


How to contact us

CONTACT YOUR ASTELLAS REPRESENTATIVE

Your sales representative can connect you with the appropriate Astellas Account Manager to help address your specific questions.

CALL TO SPEAK TO A PATIENT CARE COORDINATOR

Phone: 1-866-239-1637
Monday–Friday, 8:00 AM–8:00 PM ET

GO ONLINE

Visit VEOZAHSupportSolutions.com.

Bring the VMS conversation back to your practice.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

INDICATIONS AND USAGE

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors

WARNINGS AND PRECAUTIONS

Hepatic Transaminase Elevation

Elevations in serum transaminase [alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)] levels > 3x the upper limit of normal (ULN) occurred in 2.3% of women receiving VEOZAH and 0.9% of women receiving placebo in three clinical trials. No serum elevations in total bilirubin (> 2x ULN) occurred. Women with ALT or AST elevations were generally asymptomatic. Transaminase levels returned to pretreatment levels (or close to these) without sequelae with dose continuation, and upon dose interruption, or discontinuation. Women with cirrhosis were not studied.

Perform baseline bloodwork to evaluate for hepatic function and injury prior to VEOZAH initiation. Do not start VEOZAH if concentration of ALT or AST is ≥ 2x ULN or if the total bilirubin is elevated (e.g., ≥ 2x ULN) for the evaluating laboratory. If baseline hepatic transaminase evaluation is < 2x ULN and the total bilirubin is normal, VEOZAH can be started. Perform follow-up evaluations of hepatic transaminase concentration at 3 months, 6 months, and 9 months after initiation of therapy and when symptoms (such as nausea, vomiting, or yellowing of the skin or eyes) suggest liver injury.

ADVERSE REACTIONS

The most common adverse reactions with VEOZAH ≥ 2% and > placebo (VEOZAH % vs. placebo %) are: abdominal pain (4.3% vs. 2.1%), diarrhea (3.9% vs. 2.6%), insomnia (3.9% vs. 1.8%), back pain (3.0% vs. 2.1%), hot flush (2.5% vs. 1.6%), and hepatic transaminase elevation (2.3% vs. 0.8%).

Please click here for full Prescribing Information for VEOZAH™ (fezolinetant).

REFERENCES: 1. VEOZAH [package insert]. Northbrook, IL: Astellas Pharma US, Inc. 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55.